GlaxoSmithKline News and Research

RSS

Neurocrine Biosciences announces GSK561679 antagonist's efficacy in major depressive disorder

Neurocrine Biosciences, Inc. today announced top-line efficacy and safety results from a Phase II clinical trial utilizing Corticotropin Releasing Factor (CRF1) receptor antagonist GSK561679 in patients currently experiencing a major depressive episode.

15 Sep 2010

Genmab announces update in corporate strategy

Genmab A/S announced today an update to its corporate strategy. Today's strategy update represents a new beginning for Genmab where we acknowledge our successes and learn from our mistakes.

14 Sep 2010

iPierian raises $28 million from Series B equity financing closure

iPierian, Inc., the leading biopharmaceutical company using patient-derived induced pluripotent stem cells (iPSCs) for drug discovery, today announced the second closing of its Series B equity financing, bringing the total amount raised in this round to $28 million.

9 Sep 2010

$GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL$

GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL

GlaxoSmithKline and Genmab A/S announced today the start of a Phase III study in patients with indolent B-cell non-Hodgkin's lymphoma (B-NHL) who did not respond to or progressed during, or within 6 months of a rituximab containing regimen.

9 Sep 2010

Standard dose of UFH optimal for treatment of PCI patients on fondaparinux: Study

A landmark international study, coordinated by McMaster University, has found that lower doses of a blood thinner called unfractionated heparin (UFH) during angioplasty did not reduce bleeding or vascular complications compared to standard dose UFH in patients initially treated with a blood thinner, fondaparinux.

31 Aug 2010

FDA extends Prescription Drug User Fee Act date for ezogabine

GlaxoSmithKline and Valeant Pharmaceuticals International announced today the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for ezogabine to 30 November 2010.

31 Aug 2010

Wall Street Journal reports on pharma's growing interest in emerging markets

Abbott Laboratories will soon acquire the biggest share of India's pharmaceuticals market, about 7%, when the company closes as early as next month on a $3.7 billion takeover of the drugs business of Piramal Healthcare Ltd

27 Aug 2010

Specific type of neurons determine frightening stimulus reaction: Research

Fear can make you run, it can make you fight, and it can glue you to the spot. Scientists at the European Molecular Biology Laboratory (EMBL) in Monterotondo, Italy and GlaxoSmithKline in Verona, Italy, have identified not only the part of the brain but the specific type of neurons that determine how mice react to a frightening stimulus.

26 Aug 2010

Two diabetes medications increase risk of heart attack, failure: Study

In contrast to previous reports, the risks of the composite endpoint of heart attack, heart failure, both, or death were the same about 4 percent for patients taking the diabetes drugs rosiglitazone or pioglitazone, according to a study published in the American Heart Association journal Circulation: Cardiovascular Quality and Outcomes.

25 Aug 2010

Survey finds women interested in human papillomavirus vaccination

Cost but not convenience plays a significant role in attitudes about vaccination for common human papillomaviruses for women over the age of 26, according to the authors of a recent article in the journal Sexual Health.

25 Aug 2010

FDA grants priority review designation of BENLYSTA for systemic lupus erythematosus treatment

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced that the U.S. Food and Drug Administration has granted a priority review designation to BENLYSTA (belimumab) as a potential treatment for systemic lupus erythematosus.

20 Aug 2010

Novartis sales representatives increase calls to healthcare providers by 7%: SDI report

In the first 6 months of 2010, according to SDI, calls made by Novartis sales representatives to physicians, nurse practitioners, and physician assistants increased 7% compared with the last 6 months of 2009.

19 Aug 2010

UK scientists receive Royal Society awards for cancer research

Two Cancer Research UK scientists were recently awarded prestigious Royal Society Awards, while a number of Cancer Research UK scientists were elected fellows of the Royal Society and the Academy of Medical Sciences.Dr Tomas Lindahl is the recipient of the Royal Society Copley Medal, the world's oldest prize for scientific achievement, and Professor Stephen West is awarded this year's GlaxoSmithKline Prize and Lecture.

18 Aug 2010

MMV joins Pool for Open Innovation against neglected tropical diseases

The Medicines for Malaria Venture (MMV) today became the first product development partnership (PDP) to contribute intellectual property to the Pool for Open Innovation against Neglected Tropical Diseases. MMV joins GlaxoSmithKline (GSK), Alnylam Pharmaceuticals, and the Massachusetts Institute of Technology (MIT) in contributing to the Pool, which is administered by BIO Ventures for Global Health (BVGH).

17 Aug 2010

Intercell reports significant increase in second quarter revenue

Today, Intercell AG announced its financial results for Q2 and H1 2010.IXIARO/JESPECT sales increased significantly from EUR 2.4m in Q2 2009 to EUR 5.2m in Q2 2010 Continued focus on growing marketing and sales of product in traveler and military markets

17 Aug 2010

Global vaccine sales up 16% in 2009, report says

Global vaccine sales "grew by a healthy 16 percent last year, when sales shot up to $22.1 billion, healthcare market research publisher Kalorama Information reported Friday," according to the Associated Press. Kalorama is also forecasting sales "will rise at a compound annual rate of 9.7 percent during the next five years," (Johnson, 8/14).

17 Aug 2010

Pro-Pharmaceuticals second-quarter net loss applicable to common stock decreases to $2.5 million

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today reported its financial results for the second quarter and the first six months ended June 30, 2010. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the SEC.

13 Aug 2010

Lamictal can cause aseptic meningitis: FDA

The U.S. Food and Drug Administration today warned that the drug Lamictal (lamotrigine), approved to treat seizures and bipolar disorder, can cause aseptic meningitis, an inflammation of the protective membranes (meninges) that cover the brain and spinal cord not caused by bacterial infection.The agency is working with the drug's manufacturer, GlaxoSmithKline, to update the prescribing information and patient medication guide to include this risk.

13 Aug 2010

FDA advisory committee votes in favor of Ezogabine

The U.S. Food and Drug Administration advisory committee voted unanimously that clinical studies had provided substantial evidence of the effectiveness of Ezogabine (known as Retigabine outside of the U.S.) as adjunctive treatment for adults with partial-onset seizures.

12 Aug 2010

FDA advisory committee votes in favor of investigational anti-epileptic drug ezogabine

GlaxoSmithKline and Valeant Pharmaceuticals International announced today that a U.S. Food and Drug Administration advisory committee voted unanimously that clinical studies had provided substantial evidence of the effectiveness of ezogabine as adjunctive treatment for adults with partial-onset seizures.

12 Aug 2010

GlaxoSmithKline News and Research

Neurocrine Biosciences announces GSK561679 antagonist's efficacy in major depressive disorder

Genmab announces update in corporate strategy

iPierian raises $28 million from Series B equity financing closure

GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL

Standard dose of UFH optimal for treatment of PCI patients on fondaparinux: Study

FDA extends Prescription Drug User Fee Act date for ezogabine

Wall Street Journal reports on pharma's growing interest in emerging markets

Specific type of neurons determine frightening stimulus reaction: Research

Two diabetes medications increase risk of heart attack, failure: Study

Survey finds women interested in human papillomavirus vaccination

FDA grants priority review designation of BENLYSTA for systemic lupus erythematosus treatment

Novartis sales representatives increase calls to healthcare providers by 7%: SDI report

UK scientists receive Royal Society awards for cancer research

MMV joins Pool for Open Innovation against neglected tropical diseases

Intercell reports significant increase in second quarter revenue

Global vaccine sales up 16% in 2009, report says

Pro-Pharmaceuticals second-quarter net loss applicable to common stock decreases to $2.5 million

Lamictal can cause aseptic meningitis: FDA

FDA advisory committee votes in favor of Ezogabine

FDA advisory committee votes in favor of investigational anti-epileptic drug ezogabine

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News